Does Dr. BENJAMIN RUSHING have financial conflicts of interest?

Dr. BENJAMIN RUSHING (MD) has received a total of $1,608 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,608 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. BENJAMIN RUSHING?

According to CMS Open Payments data, Dr. BENJAMIN RUSHING received funding from GENZYME CORPORATION ($462), UCB ($191), and NOVARTIS PHARMACEUTICALS CORPORATION ($170).

Does Dr. BENJAMIN RUSHING receive research grants or speaking fees?

Dr. BENJAMIN RUSHING has received $1,608 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. BENJAMIN RUSHING

MDReal-Time Hydrated

Specialty: Student in an Organized Health Care Education/Training Program

Practice Location: JACKSON, MS 39216

NPI Number: 1073254256

LIFETIME INDUSTRY VALUE

$1,608

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. RUSHING is a verified Student in an Organized Health Care Education/Training Program practitioner based in JACKSON, MS.

Between 2021 and 2025, Dr. RUSHING had an overall industry promotional and research financial footprint of $1,608 as recorded in the federal CMS Open Payments database.

$1,608 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. RUSHING's primary funding source is GENZYME CORPORATION, which accounts for $462 (representing 28.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENZYME CORPORATION

Rank 1

$462

28.7%

UCB

Rank 2

$191

11.9%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 3

$170

10.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.